TWI332499B - Chemical compounds - Google Patents

Chemical compounds Download PDF

Info

Publication number
TWI332499B
TWI332499B TW093112840A TW93112840A TWI332499B TW I332499 B TWI332499 B TW I332499B TW 093112840 A TW093112840 A TW 093112840A TW 93112840 A TW93112840 A TW 93112840A TW I332499 B TWI332499 B TW I332499B
Authority
TW
Taiwan
Prior art keywords
methyl
ethyl
cns
ministry
intellectual property
Prior art date
Application number
TW093112840A
Other languages
English (en)
Chinese (zh)
Other versions
TW200510309A (en
Inventor
Giuseppe Alvaro
Luca Arista
Francesca Cardullo
Adamo Lucilla D
Aldo Feriani
Riccardo Giovannini
Catia Seri
Original Assignee
Glaxo Group Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Glaxo Group Ltd filed Critical Glaxo Group Ltd
Publication of TW200510309A publication Critical patent/TW200510309A/zh
Application granted granted Critical
Publication of TWI332499B publication Critical patent/TWI332499B/zh

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/06—Antiabortive agents; Labour repressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32—Alcohol-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36—Opioid-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/08—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
    • C07D211/18—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D211/34—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Psychiatry (AREA)
  • Addiction (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Pain & Pain Management (AREA)
  • Hospice & Palliative Care (AREA)
  • Gynecology & Obstetrics (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Urology & Nephrology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Vascular Medicine (AREA)
  • Anesthesiology (AREA)
  • Cardiology (AREA)
  • Emergency Medicine (AREA)
  • Pregnancy & Childbirth (AREA)
  • Reproductive Health (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pyrrole Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
TW093112840A 2003-05-09 2004-05-07 Chemical compounds TWI332499B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB0310724.0A GB0310724D0 (en) 2003-05-09 2003-05-09 Chemical compounds

Publications (2)

Publication Number Publication Date
TW200510309A TW200510309A (en) 2005-03-16
TWI332499B true TWI332499B (en) 2010-11-01

Family

ID=9957781

Family Applications (1)

Application Number Title Priority Date Filing Date
TW093112840A TWI332499B (en) 2003-05-09 2004-05-07 Chemical compounds

Country Status (21)

Country Link
US (2) US20070073061A1 (ko)
EP (1) EP1622871A1 (ko)
JP (1) JP4684221B2 (ko)
KR (1) KR20060009313A (ko)
CN (1) CN100534983C (ko)
AR (1) AR044269A1 (ko)
AU (1) AU2004235967B2 (ko)
BR (1) BRPI0410154A (ko)
CA (1) CA2524894A1 (ko)
EG (1) EG24668A (ko)
GB (1) GB0310724D0 (ko)
IS (1) IS8164A (ko)
MA (1) MA27795A1 (ko)
MX (1) MXPA05012096A (ko)
MY (1) MY140027A (ko)
NO (1) NO20055835L (ko)
NZ (1) NZ543068A (ko)
RU (1) RU2392270C2 (ko)
TW (1) TWI332499B (ko)
WO (1) WO2004099143A1 (ko)
ZA (1) ZA200508339B (ko)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0412865D0 (en) 2004-06-09 2004-07-14 Glaxo Group Ltd Chemical compounds
US7844037B2 (en) 2005-08-08 2010-11-30 Palm, Inc. Method and device for enabling message responses to incoming phone calls
EP2094692B1 (en) * 2006-11-01 2012-11-28 Bristol-Myers Squibb Company Modulators of glucocorticoid receptor, ap-1 and/or nf-kappab activity and use thereof
KR20110049866A (ko) * 2008-09-01 2011-05-12 뉴로서치 에이/에스 피페리딘-4-아세트아미드 유도체 및 모노아민 신경전달물질 재흡수 억제제로서의 이의 용도
ES2672099T3 (es) 2011-07-04 2018-06-12 Irbm - Science Park S.P.A. Antagonistas del receptor NK-1 para el tratamiento de la neovascularización corneal
CN106187999A (zh) * 2015-05-04 2016-12-07 复旦大学 取代哌啶类化合物及其制备方法和用途
IL306022A (en) 2021-03-23 2023-11-01 Bioage Labs Inc NLRP3 inflammasome inhibitors
WO2023147468A1 (en) 2022-01-28 2023-08-03 BioAge Labs, Inc. N-oxide inhibitors of nlrp3 inflammasome

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US309720A (en) * 1884-12-23 William p
NL262366A (ko) * 1960-03-14
GB1356117A (en) * 1970-12-16 1974-06-12 Searle & Co 1-3-cyano-3,3-diphenylpropyl-4-phenylpiperidine-4-carboxylic acid derivatives
US5635510A (en) * 1993-05-06 1997-06-03 Merrell Pharmaceuticals Inc. Substituted pyrrolidin-3-yl-alkyl-piperidines
DE19603767A1 (de) * 1996-02-02 1997-08-07 Hoechst Ag Pyrrolidinpropionsäurederivate mit bradykinin-antagonistischer Wirkung
US6020347A (en) * 1997-11-18 2000-02-01 Merck & Co., Inc. 4-substituted-4-piperidine carboxamide derivatives
WO1999025685A1 (en) * 1997-11-18 1999-05-27 Merck & Co., Inc. 4-substituted-4-piperidine carboxamide derivatives
US6423519B1 (en) * 1998-07-15 2002-07-23 Gpc Biotech Inc. Compositions and methods for inhibiting fungal growth
WO2002083134A1 (en) * 2001-04-12 2002-10-24 Pharmacopeia, Inc. Aryl and biaryl piperidines used as mch antagonists
WO2003045918A1 (en) * 2001-11-26 2003-06-05 Schering Corporation Piperidine-based mch antagonists for treatment of obesity and cns disorders
TW200403058A (en) * 2002-04-19 2004-03-01 Bristol Myers Squibb Co Heterocyclo inhibitors of potassium channel function
ATE453621T1 (de) * 2002-07-03 2010-01-15 Glaxo Group Ltd Substituierte 4-phenylpiperidinamide als tachykininantagonisten und serotoninwiederaufnahmehemmer

Also Published As

Publication number Publication date
US20070073061A1 (en) 2007-03-29
GB0310724D0 (en) 2003-06-11
MY140027A (en) 2009-11-30
IS8164A (is) 2005-12-01
JP2006525975A (ja) 2006-11-16
EP1622871A1 (en) 2006-02-08
NO20055835L (no) 2006-02-07
KR20060009313A (ko) 2006-01-31
MXPA05012096A (es) 2006-02-08
AR044269A1 (es) 2005-09-07
AU2004235967A1 (en) 2004-11-18
CA2524894A1 (en) 2004-11-18
EG24668A (en) 2010-04-11
TW200510309A (en) 2005-03-16
NO20055835D0 (no) 2005-12-08
AU2004235967B2 (en) 2008-10-23
MA27795A1 (fr) 2006-03-01
RU2005138315A (ru) 2007-06-20
JP4684221B2 (ja) 2011-05-18
WO2004099143A1 (en) 2004-11-18
ZA200508339B (en) 2006-10-25
BRPI0410154A (pt) 2006-05-16
CN100534983C (zh) 2009-09-02
US20090192194A1 (en) 2009-07-30
CN1819995A (zh) 2006-08-16
RU2392270C2 (ru) 2010-06-20
NZ543068A (en) 2009-07-31

Similar Documents

Publication Publication Date Title
JP3294611B2 (ja) ５−ｈｔ４レセプター・アンタゴニスト
TW199144B (ko)
TWI242004B (en) 1-(1-substituted-4-piperidinyl)methyl-4-piperidine derivatives, process for producing the same, medicinal compositions containing the same and intermediates of these compounds
US5610165A (en) N-acylpiperidine tachykinin antagonists
EP0414289B1 (en) Spirocyclic antipsychotic agents
TW200540169A (en) Mtp inhibiting aryl piperidines or piperazines substituted with 5-membered heterocycles
US5116846A (en) N-aralkyl piperidine derivatives as psychotropic drugs
TWI358298B (en) Substituted 4-alkyl- and 4-alkanoyl-piperidine der
JPH09500875A (ja) タキキニン拮抗薬としての４−フェニル−４−フェニルプロピル（エチル）−ピペリジン
JPH08502741A (ja) ５−ｈｔ▲下４▼レセプターアンタゴニスト用のピペリジン誘導体
GB2271774A (en) Piperazine derivatives
WO2007148208A2 (en) Carbonylated (aza) cyclohexanes as dopamine d3 receptor ligands
JPH07113013B2 (ja) 新規なピペリジン、テトラヒドロピリジンおよびピロリジン誘導体およびこれらを含有する製薬組成物
JP2005537293A (ja) Ｎ−［フェニル（ピペリジン−２−イル）メチル］ベンズアミド誘導体、その製造法、およびその治療用途
TW200902518A (en) Substituted heterocyclic derivatives and their pharmaceutical use and compositions
CA2068527A1 (en) Muscarinic receptor antagonists
SK6112003A3 (en) Amidoalkyl-piperidine and amidoalkyl-piperazine derivatives for the treatment of nervous system disorders
CN102105458B (zh) 作为nk1受体的拮抗剂的5-[5-[2-(3,5-双(三氟甲基)苯基)-2-甲基丙酰基甲基氨基]-4-(4-氟-2-甲基苯基)]-2-吡啶基-2-烷基-脯氨酰胺
TWI332499B (en) Chemical compounds
JP2010523495A (ja) サブタイプ選択的アザビシクロアルカン誘導体
JPH08502283A (ja) ５−ｈｔ▲下４▼レセプターアンタゴニスト用の縮合環系ｎ−アルキルピペリジニル−４−メチルカルボン酸エステル／アミド
EA012726B1 (ru) Производные пиррола, их получение и их применение в терапии
CA2317515A1 (en) Oxazole derivatives as serotonin-1a receptor agonists
TW201206910A (en) Substituted N-heterocycloalkyl bipyrrolidinylphenyl amide derivatives, preparation and therapeutic use thereof
JP2008501759A (ja) 種々の疾患の処置に有用なイミダゾール−２−オン化合物

Legal Events

Date Code Title Description
MM4A Annulment or lapse of patent due to non-payment of fees